Ranbaxy/Teva Prohibited From Marketing Generic Quinapril
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal appeals court affirmed a district court decision Nov. 22 that Teva/Ranbaxy's generic quinapril must remain off the market.
You may also be interested in...
Accupril Generics Come Off The Market Following Preliminary Injunction
Teva and Ranbaxy plan to appeal the district court ruling in favor of Pfizer to the federal appeals court. Pfizer said it will seek damages for lost Accupril sales since the December launch of Teva/Ranbaxy’s quinapril.
Teva/Ranbaxy Launch First Generic Of Pfizer’s Accupril
Teva, which relinquished 180-day exclusivity, is marketing quinapril manufactured under Ranbaxy’s ANDA pursuant to a supply and distribution agreement. Teva/Ranbaxy’s product gets a jump on at least five other potential generic competitors; timing of the generic’s launch may have been earlier than expected by Pfizer.
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue